BEGIN:VCALENDAR VERSION:2.0 PRODID:-//swoogo.com//NONSGML kigkonsult.se iCalcreator 2.41.90// CALSCALE:GREGORIAN UID:31346566-6634-4163-a230-333537353364 BEGIN:VEVENT UID:65adfeba551fb4b1ce0203f48a71b6cc9af15c9b@swoogo.com DTSTAMP:20261008T004104Z DESCRIPTION:Opioid use remains a significant public health concern in Ameri ca. The epidemic further resulted in significant increases in justice-invo lved persons with a history of opioid use with as much as 15% of incarcera ted persons having an Opioid Use Disorder. The literature describes pharma cotherapies for opioid use in combination with counseling as the gold stan dard for treating Opioid Use Disorder (OUD). Elizabeth Detention Facility\ , a 300-bed Immigration and Customs Enforcement ICE) Health Service Corps (IHSC) facility\, noted increases in requests to manage patients with acti ve opioid use or a history of opioid pharmacotherapy. The facility leaders hip team began to develop local OUD treatment program using opioid pharmac otherapy and training to address staff confidence with managing the popula tion. The Health Administrator and the Lead Pharmacist began by coordinati ng access to medication. We determined that IHSC's formulary included bupr enorphine products. The pharmacist secured a supply of buprenorphine via o ur pharmaceutical supplier. The pharmacy and local leadership team develop ed procedures for securely storing\, accounting\, and dispensing the medic ation. This preparation proved prescient as correctional placement options for patients with OUD in the immediate vicinity diminished. As the politi cal climate toward immigration shifted in the state\, many local correctio nal facilities were no longer willing to house noncitizens. Our onsite psy chiatrists led training on recognizing withdrawal symptoms for alcohol\, b enzodiazepine\, and opioids. The Clinical Director provided additional tra ining on the use of the Clinical Opioid Withdrawal Scale (COWS). The pharm acist provided training on the proper administration of the sublingual fil ms to the nursing staff. Our staff physician obtained a buprenorphine waiv er as a back-up provider. We included training to support clinical staff c ompetence with managing patients in active withdrawal from OUD. Finally\, a physician evaluated patients prior to leaving ICE custody or transitioni ng to another facility to ensure they had access to adequate medication an d continuity of care. At the outset\, our program goals included the intro duction of an opioid detoxification program to our clinic. Moreover\, the program ensured IHSC Elizabeth could meet local program needs given the sh ifting environment. The opioid detoxification program at IHSC Elizabeth re sulted in a successful demonstration project at the facility. In conclusio n\, IHSC Elizabeth successfully provided opioid pharmacotherapy to 22 pers ons during 2023. The program ensured the provision of care that aligned wi th best practice recommendations for opioid detoxification treatment. As t he opioid crisis continues to evolve and impact justice-involved persons\, due consideration should be given to expanding capacity to manage this pa tient population in ICE detention health settings. Expanded capacity might include additional training to support staff competence and comfort\, evi dence-based clinical guidance\, and access to medication in all ICE detent ion health settings. DTSTART:20250306T163000Z DTEND:20250306T173000Z LAST-MODIFIED:20261008T004104Z LOCATION: SEQUENCE:0 STATUS:CONFIRMED SUMMARY:Implementation of an Opioid Use Disorder Program in an ICE Health S ervice Corps (IHSC) Facility TRANSP:OPAQUE X-ALT-DESC;FMTTYPE=text/html:

Opioid use remains a significant public hea lth concern in America. The epidemic further resulted in significant incre ases in justice-involved persons with a history of opioid use with as much as 15% of incarcerated persons having an Opioid Use Disorder. The literat ure describes pharmacotherapies for opioid use in combination with counsel ing as the gold standard for treating Opioid Use Disorder (OUD). Elizabeth Detention Facility\, a 300-bed Immigration and Customs Enforcement ICE) H ealth Service Corps (IHSC) facility\, noted increases in requests to manag e patients with active opioid use or a history of opioid pharmacotherapy. The facility leadership team began to develop local OUD treatment program using opioid pharmacotherapy and training to address staff confidence with managing the population. The Health Administrator and the Lead Pharmacist began by coordinating access to medication. We determined that IHSC's for mulary included buprenorphine products. The pharmacist secured a supply of buprenorphine via our pharmaceutical supplier. The pharmacy and local lea dership team developed procedures for securely storing\, accounting\, and dispensing the medication. This preparation proved prescient as correction al placement options for patients with OUD in the immediate vicinity dimin ished. As the political climate toward immigration shifted in the state\, many local correctional facilities were no longer willing to house nonciti zens. Our onsite psychiatrists led training on recognizing withdrawal symp toms for alcohol\, benzodiazepine\, and opioids. The Clinical Director pro vided additional training on the use of the Clinical Opioid Withdrawal Sca le (COWS). The pharmacist provided training on the proper administration o f the sublingual films to the nursing staff. Our staff physician obtained a buprenorphine waiver as a back-up provider. We included training to supp ort clinical staff competence with managing patients in active withdrawal from OUD. Finally\, a physician evaluated patients prior to leaving ICE cu stody or transitioning to another facility to ensure they had access to ad equate medication and continuity of care. At the outset\, our program goal s included the introduction of an opioid detoxification program to our cli nic. Moreover\, the program ensured IHSC Elizabeth could meet local progra m needs given the shifting environment. The opioid detoxification program at IHSC Elizabeth resulted in a successful demonstration project at the fa cility. In conclusion\, IHSC Elizabeth successfully provided opioid pharma cotherapy to 22 persons during 2023. The program ensured the provision of care that aligned with best practice recommendations for opioid detoxifica tion treatment. As the opioid crisis continues to evolve and impact justic e-involved persons\, due consideration should be given to expanding capaci ty to manage this patient population in ICE detention health settings. Exp anded capacity might include additional training to support staff competen ce and comfort\, evidence-based clinical guidance\, and access to medicati on in all ICE detention health settings.

BEGIN:VALARM UID:33343839-3537-4630-b133-623739613830 ACTION:DISPLAY DESCRIPTION:Opioid use remains a significant public health concern in Ameri ca. The epidemic further resulted in significant increases in justice-invo lved persons with a history of opioid use with as much as 15% of incarcera ted persons having an Opioid Use Disorder. The literature describes pharma cotherapies for opioid use in combination with counseling as the gold stan dard for treating Opioid Use Disorder (OUD). Elizabeth Detention Facility\ , a 300-bed Immigration and Customs Enforcement ICE) Health Service Corps (IHSC) facility\, noted increases in requests to manage patients with acti ve opioid use or a history of opioid pharmacotherapy. The facility leaders hip team began to develop local OUD treatment program using opioid pharmac otherapy and training to address staff confidence with managing the popula tion. The Health Administrator and the Lead Pharmacist began by coordinati ng access to medication. We determined that IHSC's formulary included bupr enorphine products. The pharmacist secured a supply of buprenorphine via o ur pharmaceutical supplier. The pharmacy and local leadership team develop ed procedures for securely storing\, accounting\, and dispensing the medic ation. This preparation proved prescient as correctional placement options for patients with OUD in the immediate vicinity diminished. As the politi cal climate toward immigration shifted in the state\, many local correctio nal facilities were no longer willing to house noncitizens. Our onsite psy chiatrists led training on recognizing withdrawal symptoms for alcohol\, b enzodiazepine\, and opioids. The Clinical Director provided additional tra ining on the use of the Clinical Opioid Withdrawal Scale (COWS). The pharm acist provided training on the proper administration of the sublingual fil ms to the nursing staff. Our staff physician obtained a buprenorphine waiv er as a back-up provider. We included training to support clinical staff c ompetence with managing patients in active withdrawal from OUD. Finally\, a physician evaluated patients prior to leaving ICE custody or transitioni ng to another facility to ensure they had access to adequate medication an d continuity of care. At the outset\, our program goals included the intro duction of an opioid detoxification program to our clinic. Moreover\, the program ensured IHSC Elizabeth could meet local program needs given the sh ifting environment. The opioid detoxification program at IHSC Elizabeth re sulted in a successful demonstration project at the facility. In conclusio n\, IHSC Elizabeth successfully provided opioid pharmacotherapy to 22 pers ons during 2023. The program ensured the provision of care that aligned wi th best practice recommendations for opioid detoxification treatment. As t he opioid crisis continues to evolve and impact justice-involved persons\, due consideration should be given to expanding capacity to manage this pa tient population in ICE detention health settings. Expanded capacity might include additional training to support staff competence and comfort\, evi dence-based clinical guidance\, and access to medication in all ICE detent ion health settings. TRIGGER:-PT15M END:VALARM END:VEVENT END:VCALENDAR